← Back to Screener
Mustang Bio, Inc. (MBIO)
Price$0.67
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-60.41%
Price vs S&P 500 (4W)-3.73%
VGM Score19.01
Market Capitalization$5.08M
All Metrics
Book Value / Share (Quarterly)$1.13
P/TBV (Annual)0.32x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.64
Price vs S&P 500 (YTD)-39.86%
EPS (TTM)$-0.49
10-Day Avg Trading Volume0.56M
EPS Excl Extra (TTM)$-0.49
EPS (Annual)$-0.39
ROI (Annual)-20.16%
Cash / Share (Quarterly)$2.15
ROA (Last FY)-10.92%
EBITD / Share (TTM)$-0.55
ROE (5Y Avg)-8452.10%
Cash Flow / Share (Annual)$-0.72
P/B Ratio0.59x
P/B Ratio (Quarterly)0.64x
Net Income / Employee (Annual)$-480,300
Net Interest Coverage (TTM)-14.83x
ROA (TTM)-16.36%
EPS Incl Extra (Annual)$-0.39
Current Ratio (Annual)2.22x
Quick Ratio (Quarterly)2.10x
3-Month Avg Trading Volume0.19M
52-Week Price Return-46.40%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.48
52-Week High$7.00
EPS Excl Extra (Annual)$-0.39
Tangible BV CAGR (5Y)-5.01%
26-Week Price Return-52.48%
Quick Ratio (Annual)2.21x
13-Week Price Return-29.42%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.12x
Enterprise Value$-11.18M
Book Value / Share Growth (5Y)-38.42%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.37
3-Month Return Std Dev59.36%
Net Income / Employee (TTM)$-680,700
ROE (Last FY)-20.16%
Net Interest Coverage (Annual)-12.90x
EPS Basic Excl Extra (Annual)$-0.39
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.49
ROI (TTM)-35.38%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.82
Price vs S&P 500 (52W)-70.77%
Year-to-Date Return-31.70%
5-Day Price Return-12.87%
EPS Normalized (Annual)$-0.39
ROA (5Y Avg)-121.58%
Month-to-Date Return-0.01%
Cash Flow / Share (TTM)$-7.66
EBITD / Share (Annual)$-0.49
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-8439.65%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.49
P/TBV (Quarterly)3.75x
P/B Ratio (Annual)0.75x
Book Value / Share (Annual)$1.31
Price vs S&P 500 (13W)-37.68%
Beta2.03x
Revenue / Share (TTM)$0.00
ROE (TTM)-35.38%
52-Week Low$0.53
mGradeF
vgmGradeF
Show chart for
Analyst Recommendations
Sep 2024
Oct 2024
Nov 2024
Dec 2024
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MBIOMustang Bio, Inc. | — | — | F | $0.67 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Mustang Bio is a clinical-stage biopharmaceutical company developing cell and gene therapies to treat hematologic cancers, solid tumors, and rare genetic diseases. The company's pipeline focuses on gene therapies for genetic disorders and CAR T cell therapies targeting hematologic malignancies and solid tumors.